272 related articles for article (PubMed ID: 18250414)
1. Inhibition of STAT3 promotes the efficacy of adoptive transfer therapy using type-1 CTLs by modulation of the immunological microenvironment in a murine intracranial glioma.
Fujita M; Zhu X; Sasaki K; Ueda R; Low KL; Pollack IF; Okada H
J Immunol; 2008 Feb; 180(4):2089-98. PubMed ID: 18250414
[TBL] [Abstract][Full Text] [Related]
2. Systemic inhibition of transforming growth factor-beta in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccines.
Ueda R; Fujita M; Zhu X; Sasaki K; Kastenhuber ER; Kohanbash G; McDonald HA; Harper J; Lonning S; Okada H
Clin Cancer Res; 2009 Nov; 15(21):6551-9. PubMed ID: 19861464
[TBL] [Abstract][Full Text] [Related]
3. Synergistic antitumor effects of CpG oligodeoxynucleotide and STAT3 inhibitory agent JSI-124 in a mouse melanoma tumor model.
Molavi O; Ma Z; Hamdy S; Lai R; Lavasanifar A; Samuel J
Immunol Cell Biol; 2008; 86(6):506-14. PubMed ID: 18392040
[TBL] [Abstract][Full Text] [Related]
4. Adoptive transfer of type 1 CTL mediates effective anti-central nervous system tumor response: critical roles of IFN-inducible protein-10.
Nishimura F; Dusak JE; Eguchi J; Zhu X; Gambotto A; Storkus WJ; Okada H
Cancer Res; 2006 Apr; 66(8):4478-87. PubMed ID: 16618775
[TBL] [Abstract][Full Text] [Related]
5. Treatment of murine gliomas by adoptive transfer of ex vivo activated tumor-draining lymph node cells.
Plautz GE; Touhalisky JE; Shu S
Cell Immunol; 1997 Jun; 178(2):101-7. PubMed ID: 9225000
[TBL] [Abstract][Full Text] [Related]
6. Effective Treatment of Established GL261 Murine Gliomas through Picornavirus Vaccination-Enhanced Tumor Antigen-Specific CD8+ T Cell Responses.
Renner DN; Jin F; Litterman AJ; Balgeman AJ; Hanson LM; Gamez JD; Chae M; Carlson BL; Sarkaria JN; Parney IF; Ohlfest JR; Pirko I; Pavelko KD; Johnson AJ
PLoS One; 2015; 10(5):e0125565. PubMed ID: 25933216
[TBL] [Abstract][Full Text] [Related]
7. Radiation with STAT3 Blockade Triggers Dendritic Cell-T cell Interactions in the Glioma Microenvironment and Therapeutic Efficacy.
Ott M; Kassab C; Marisetty A; Hashimoto Y; Wei J; Zamler D; Leu JS; Tomaszowski KH; Sabbagh A; Fang D; Gupta P; Priebe W; Zielinski RJ; Burks JK; Long JP; Kong LY; Fuller GN; DeGroot J; Sulman EP; Heimberger AB
Clin Cancer Res; 2020 Sep; 26(18):4983-4994. PubMed ID: 32605912
[TBL] [Abstract][Full Text] [Related]
8. Sequential delivery of interferon-alpha gene and DCs to intracranial gliomas promotes an effective antitumor response.
Tsugawa T; Kuwashima N; Sato H; Fellows-Mayle WK; Dusak JE; Okada K; Papworth GD; Watkins SC; Gambotto A; Yoshida J; Pollack IF; Okada H
Gene Ther; 2004 Nov; 11(21):1551-8. PubMed ID: 15343358
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic effects of tumor-reactive type 1 and type 2 CD8+ T cell subpopulations in established pulmonary metastases.
Dobrzanski MJ; Reome JB; Dutton RW
J Immunol; 1999 Jun; 162(11):6671-80. PubMed ID: 10352285
[TBL] [Abstract][Full Text] [Related]
10. Stat3 inhibition activates tumor macrophages and abrogates glioma growth in mice.
Zhang L; Alizadeh D; Van Handel M; Kortylewski M; Yu H; Badie B
Glia; 2009 Oct; 57(13):1458-67. PubMed ID: 19306372
[TBL] [Abstract][Full Text] [Related]
11. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice.
Blaskovich MA; Sun J; Cantor A; Turkson J; Jove R; Sebti SM
Cancer Res; 2003 Mar; 63(6):1270-9. PubMed ID: 12649187
[TBL] [Abstract][Full Text] [Related]
12. Poly-ICLC promotes the infiltration of effector T cells into intracranial gliomas via induction of CXCL10 in IFN-alpha and IFN-gamma dependent manners.
Zhu X; Fallert-Junecko BA; Fujita M; Ueda R; Kohanbash G; Kastenhuber ER; McDonald HA; Liu Y; Kalinski P; Reinhart TA; Salazar AM; Okada H
Cancer Immunol Immunother; 2010 Sep; 59(9):1401-9. PubMed ID: 20549206
[TBL] [Abstract][Full Text] [Related]
13. Exosomes from Dendritic Cells Loaded with Chaperone-Rich Cell Lysates Elicit a Potent T Cell Immune Response Against Intracranial Glioma in Mice.
Bu N; Wu H; Zhang G; Zhan S; Zhang R; Sun H; Du Y; Yao L; Wang H
J Mol Neurosci; 2015 Jul; 56(3):631-43. PubMed ID: 25680514
[TBL] [Abstract][Full Text] [Related]
14. Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity.
Kemp RA; Ronchese F
J Immunol; 2001 Dec; 167(11):6497-502. PubMed ID: 11714817
[TBL] [Abstract][Full Text] [Related]
15. Development of a poly(d,l-lactic-co-glycolic acid) nanoparticle formulation of STAT3 inhibitor JSI-124: implication for cancer immunotherapy.
Molavi O; Mahmud A; Hamdy S; Hung RW; Lai R; Samuel J; Lavasanifar A
Mol Pharm; 2010 Apr; 7(2):364-74. PubMed ID: 20030320
[TBL] [Abstract][Full Text] [Related]
16. Immunomodulatory and anticancer effects of intra-tumoral co-delivery of synthetic lipid A adjuvant and STAT3 inhibitor, JSI-124.
Molavi O; Ma Z; Hamdy S; Lavasanifar A; Samuel J
Immunopharmacol Immunotoxicol; 2009 Jun; 31(2):214-21. PubMed ID: 18798092
[TBL] [Abstract][Full Text] [Related]
17. Glioma-derived galectin-1 regulates innate and adaptive antitumor immunity.
Verschuere T; Toelen J; Maes W; Poirier F; Boon L; Tousseyn T; Mathivet T; Gerhardt H; Mathieu V; Kiss R; Lefranc F; Van Gool SW; De Vleeschouwer S
Int J Cancer; 2014 Feb; 134(4):873-84. PubMed ID: 23929302
[TBL] [Abstract][Full Text] [Related]
18. STAT3 Inhibition Enhances the Therapeutic Efficacy of Immunogenic Chemotherapy by Stimulating Type 1 Interferon Production by Cancer Cells.
Yang H; Yamazaki T; Pietrocola F; Zhou H; Zitvogel L; Ma Y; Kroemer G
Cancer Res; 2015 Sep; 75(18):3812-22. PubMed ID: 26208907
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-23-expressing bone marrow-derived neural stem-like cells exhibit antitumor activity against intracranial glioma.
Yuan X; Hu J; Belladonna ML; Black KL; Yu JS
Cancer Res; 2006 Mar; 66(5):2630-8. PubMed ID: 16510582
[TBL] [Abstract][Full Text] [Related]
20. Synergistic Combination of Oncolytic Virotherapy and Immunotherapy for Glioma.
Tang B; Guo ZS; Bartlett DL; Yan DZ; Schane CP; Thomas DL; Liu J; McFadden G; Shisler JL; Roy EJ
Clin Cancer Res; 2020 May; 26(9):2216-2230. PubMed ID: 32019860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]